Phase-change-material-based low-loss visible-frequency hyperbolic metamaterials for ultrasensitive label-free biosensing

Hyperbolic metamaterials (HMMs) have emerged as a burgeoning field of research over the past few years as their dispersion can be easily engineered in different spectral regions using various material combinations. Even though HMMs have comparatively low optical loss due to a single resonance, the n...

Full description

Saved in:
Bibliographic Details
Main Authors: Sreekanth, Kandammathe Valiyaveedu, Ouyang, Qingling, Sreejith, Sivaramapanicker, Zeng, Shuwen, Wu, Lishu, Ilker, Efe, Dong, Weiling, Mohamed ElKabbash, Yu, Ting, Lim, Chwee Teck, Hinczewski, Michael, Strangi, Giuseppe, Yong, Ken-Tye, Simpson, Robert E., Singh, Ranjan
Other Authors: School of Physical and Mathematical Sciences
Format: Article
Language:English
Published: 2021
Subjects:
Online Access:https://hdl.handle.net/10356/151670
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Nanyang Technological University
Language: English
Description
Summary:Hyperbolic metamaterials (HMMs) have emerged as a burgeoning field of research over the past few years as their dispersion can be easily engineered in different spectral regions using various material combinations. Even though HMMs have comparatively low optical loss due to a single resonance, the noble-metal-based HMMs are limited by their strong energy dissipation in metallic layers at visible frequencies. Here, the fabrication of noble-metal-free reconfigurable HMMs for visible photonic applications is experimentally demonstrated. The low-loss and active HMMs are realized by combining titanium nitride (TiN) and stibnite (Sb₂S₃) as the phase change material. A reconfigurable plasmonic biosensor platform based on active Sb₂S₃–TiN HMMs is proposed, and it is shown that significant improvement in sensitivity is possible for small molecule detection at low concentrations. In addition, a plasmonic apta-biosensor based on a hybrid platform of graphene and Sb₂S₃–TiN HMM is developed and the detection and real-time binding of thrombin concentration as low as 1 × 10⁻¹⁵ m are demonstrated. A biosensor operating in the visible range has several advantages including the availability of sources and detectors in this region, and ease of operation particularly for point-of-care applications.